ClinicalTrials.gg
Active, not recruitingNCT06481852Updated Nov 6, 2026

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

A Phase 1 interventional study of MTT with antibiotic preconditioning + fiber supplementation and MTT with antibiotic preconditioning + placebo supplementation in Pulmonary Arterial Hypertension, sponsored by University of Minnesota. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Minnesota · Phase 1, Interventional, and Supportive care

How we know

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
160th of 253
24 · median 40
Started
2024
with 12 others
Phase 1
32 of 313
2 open now
Primary completion
2027-06
later than 27 of 55 live
Registered
288th of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 160th largest by enrollment of the 253 interventional ones that give a count, is one of 13 that started in 2024, is one of 32 in phase 1, reaches primary completion later than 27 of the 55 other live ones, and was the 288th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

This pilot clinical trial will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber supplementation vs. placebo in patients with pulmonary arterial hypertension (PAH). This trial will inform development of future trials of MTT as a treatment for PAH. 24 PAH patients will be randomized to receive either MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, or placebo + placebo supplementation. MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week,12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated consent form
  • Ages 18-75
  • Diagnosis of PAH
  • On stable treatment for PAH for one month prior to enrollment
  • Able to swallow capsules
  • Able to provide blood sample and fecal sample
  • Stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and/or video visits or correspondence.

Exclusion criteria

Exclusion Criteria:

  • Dysphagia to pills
  • Clinically active inflammatory bowel disease
  • Pregnancy or breastfeeding. A pregnancy test will be obtained from females of child- bearing potential at the screening visit or day 1 (prior to the receipt of MTT). Patients with a positive pregnancy test will be excluded. A negative result will be required for subjects who are females of to receive MTT. Patients will be counseled to avoid pregnancy which is the standard of care for patients with PAH.
  • of \< 6 months
  • Presence of ileostomy or colostomy
  • Patients on (calcineurin inhibitors, prednisone ≥ 20 mg/day, methotrexate, azathioprine, immunosuppressive biologics, JAK inhibitors).
  • Patients with neutropenia (an \< 0.5 x 10 9 cells/L) obtained on a complete blood count with differential at screening
  • History of solid organ or bone marrow transplant
  • Anticipated recurrent antibiotic use (patients with frequent urinary tract infections or sinusitis)
  • History of severe anaphylactic food allergy
  • History of celiac disease
  • Patients receiving cancer chemotherapy, immunotherapy, or radiation
  • Patients with severe Irritable bowel syndrome (IBS) defined by an IBS score >250
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Drug group

    PAH patients randomized to MTT with antibiotic preconditioning + fiber supplementation

    Drug: MTT with antibiotic preconditioning + fiber supplementation

  • Active comparator
    Control 1

    MTT with antibiotic preconditioning + placebo supplementation

    Drug: MTT with antibiotic preconditioning + placebo supplementation

  • Placebo comparator
    Control 2

    placebo + placebo supplementation.

    Other: MTT with placebo + placebo supplementation.

Interventions

  • DrugMTT with antibiotic preconditioning + fiber supplementation

    MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

  • DrugMTT with antibiotic preconditioning + placebo supplementation

    MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

  • OtherMTT with placebo + placebo supplementation.

    MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

06

What researchers measure

Primary outcomes

  1. donor engraftment comparison

    The difference in donor microbiota engraftment between the three study groups at week 12

    Time frame: week 12

Secondary outcomes

  1. safety of MTT with antibiotic preconditioning and fiber supplementation in patients with PAH

    The difference in frequency of serious adverse events and other adverse events between the three study groups

    Time frame: week 12

  2. feasibility of MTT with antibiotic preconditioning and fiber supplementation in patients with PAH

    The differences in proportion of subjects taking 100% of the MTT per protocol between the three study groups

    Time frame: week 12

  3. change in inflammatory markers

    The differences in the change in circulating markers of inflammation and microbial metabolites from baseline to week 12 between the three study groups

    Time frame: week 12

  4. compare right ventricular function, measure 1

    The differences in the change in six-minute walk distance (6MWD) from baseline to week 12 between the three study groups

    Time frame: week 12

  5. compare right ventricular function

    The differences in the change in right ventricular ejection fraction from baseline to week 12 between the three study groups

    Time frame: week 12

  6. compare right ventricular function

    The differences in the change in quality of life survey from baseline to week 12 between the three study groups

    Time frame: week 12

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 45 phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's planned 32 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Oct 2026 → Jun 2027 and completion Apr 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jul 1, 2024
StartActual
Oct 28, 2024
Primary completionEst.
Jun 30, 2027was Oct 2026
CompletionEst.
Jun 30, 2027was Apr 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Primary completion
Oct 31, 2026→Jun 30, 2027
Nov 6, 2026
Study completion
Apr 30, 2027→Jun 30, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 31, 2026→Jun 30, 2027
    Study completion Apr 30, 2027→Jun 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06481852
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Oct 28, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Thenappan Thenappan, MD
principal investigator · University of Minnesota
Levi Teigen, MD, PhD
principal investigator · University of Minnesota
Alexander Khoruts, MD
principal investigator · University of Minnesota
Christopher Staley, PhD
principal investigator · University of Minnesota
Kurt Prins, MD,PhD
principal investigator · University of Minnesota
Edward Weirs, MD
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion